Drug Profile
Research programme: restenosis therapies - Avontec/BIOTRONIK
Alternative Names: AVT-03Latest Information Update: 07 Apr 2011
Price :
$50
*
At a glance
- Originator Avontec
- Class
- Mechanism of Action Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis
Most Recent Events
- 22 Aug 2005 Preclinical trials in Coronary artery restenosis in Germany (Implant)